Strategic partnerships Leverage existing collaboration with Cancer Research UK and MHRA recognition to position Aleta Biotherapeutics as a validated partner for translational oncology programs, offering access to clinical pathway expertise, regulatory support, and potential co-development opportunities.

Clinical momentum Aleta’s lead program approaching Phase 1/2 and focus on overcoming antigen loss and tumor heterogeneity suggests strong interest from biopharma in solid tumor and hematologic cancer franchises, presenting doors for licensing, joint ventures, or sponsored research arrangements.

Specialized capabilities CAR-T Engager technology with multi-antigen targeting and T cell fitness/persistence can be packaged as a platform for collaboration with companies seeking to enhance existing CAR-T therapies or develop next-generation cell therapies for difficult-to-treat cancers.

Regulatory credibility UK Innovation Passport award and MHRA pathway support enhance credibility with global regulators and potential customers, enabling faster discussions on technology transfer, clinical trial sponsorship, or compassionate use programs.

Resource-lightful partner With a small team, Aleta could partner with CROs, academic labs, or pharma for co-development, data sharing, or service engagements (assays, manufacturing support, or translational studies) to extend capabilities without immediate headcount expansion.